Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study.

Author(s): Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, Massart C, Moe SM, Monge M, Souberbielle JC

Publication: Am J Kidney Dis, 2008, Vol. 51, Page 987-95

PubMed ID: 18430500 PubMed Review Paper? No

Purpose of Paper

Conclusion of Paper

Studies

1. Study Purpose

   The purpose of this study was to determine the effects of anticoagulant, assay type and storage on the measurement of PTH in blood specimens.

   Summary of Findings:

   Anticoagulant and assay type significantly affected the measured PTH variability (both p<0.001), but storage did not. While interindividual variability accounted for 96.8% of the variability, 2.5% of the variability was attributed to kit and 0.7% to anticoagulant. Citrated plasma consistently had lower levels of PTH than EDTA plasma and serum. Importantly, the differences in anticoagulant and kit type led to different Kidney Disease Outcomes Quality Initiative (KDOQI) classifications.

   Biospecimens

   • Bodily Fluid - Plasma
   • Bodily Fluid - Serum
   • Bodily Fluid - Blood

   Preservative Types

   • Frozen

   Diagnoses:

   • Diabetes Type 2
   • Not specified

   Platform:

   Analyte	Technology Platform
   Peptide	Clinical chemistry/auto analyzer

   Pre-analytical Factors:

   Classification	Pre-analytical Factor	Value(s)
   Biospecimen Aliquots and Components	Blood and blood products	Plasma Serum
   Storage	Time at room temperature	0 h 16-22 h
   Clinical chemistry/auto analyzer Specific	Technology platform	Roche Elecsys Bayer Advia Centaur DiaSorin LIASON DPC Immulite Abbot Achitect Beckman-Coulter Access
   Biospecimen Acquisition	Anticoagulant	EDTA Sodium citrate None

   View more